Virtualscopics History

This visionary imaging technology company evolved from research initially begun in 1990 at the University of Rochester's Medical Center and School of Engineering. These early efforts were directed primarily toward the accurate and reproducible measurement of advanced image-based biomarkers such as hippocampus volume and cartilage thickness.

VirtualScopics was established in December 2000 in Rochester, New York. The Company is now a leading provider of image-based biomarkers and innovative imaging clinical trial services utilizing biomarkers for pharmaceutical development.

VirtualScopics has an extensive intellectual property portfolio of 18 patents and patents pending, covering methods, systems, and biomarkers. These techniques are the foundation of the analysis tools used in clinical trials today.

As a leader in image analysis, VirtualScopics utilizes its patented suite of image analysis algorithms to detect, measure and analyze specific biological structures from medical image data, such as those provided by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound. VirtualScopics' technology enables faster and more reliable detection of disease progression or therapeutic benefit, which can then accelerate the clinical trial process. The societal benefits include the ability to get the right drugs to market faster and ultimately save lives. Additionally, "killing" an ineffective drug early in the development cycle can save a pharmaceutical company millions of dollars.

VirtualScopics has developed successful collaborative relationships with companies such as Pfizer, Inc., who is an investor in the company as with GE Healthcare. VirtualScopics is currently working with 11 of the top 15 pharmaceutical and biotech companies in the world.